225 related articles for article (PubMed ID: 7790947)
1. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease.
Knable MB; Jones DW; Coppola R; Hyde TM; Lee KS; Gorey J; Weinberger DR
J Nucl Med; 1995 Jul; 36(7):1216-25. PubMed ID: 7790947
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
[TBL] [Abstract][Full Text] [Related]
3. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC
J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
[TBL] [Abstract][Full Text] [Related]
4. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
Reiche W; Grundmann M; Huber G
Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study.
Pizzolato G; Chierichetti F; Rossato A; Briani C; Dam M; Borsato N; Saitta B; Zanco P; Ferlin G; Battistin L
Eur Neurol; 1993; 33(2):143-8. PubMed ID: 8467821
[TBL] [Abstract][Full Text] [Related]
6. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
[TBL] [Abstract][Full Text] [Related]
7. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
[TBL] [Abstract][Full Text] [Related]
8. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.
Buck A; Westera G; Sutter M; Albani C; Kung HF; vonSchulthess GK
J Nucl Med; 1995 Jul; 36(7):1196-200. PubMed ID: 7790944
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
[TBL] [Abstract][Full Text] [Related]
10. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy.
Hertel A; Weppner M; Baas H; Schreiner M; Maul FD; Baum RP; Fischer PA; Hör G
Nucl Med Commun; 1997 Sep; 18(9):811-22. PubMed ID: 9352546
[TBL] [Abstract][Full Text] [Related]
11. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
[TBL] [Abstract][Full Text] [Related]
12. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
Pirker W; Asenbaum S; Wenger S; Kornhuber J; Angelberger P; Deecke L; Podreka I; Brücke T
J Nucl Med; 1997 Nov; 38(11):1711-7. PubMed ID: 9374338
[TBL] [Abstract][Full Text] [Related]
13. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
[TBL] [Abstract][Full Text] [Related]
14. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
[TBL] [Abstract][Full Text] [Related]
15. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
[TBL] [Abstract][Full Text] [Related]
16. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
Hierholzer J; Cordes M; Schelosky L; Sander B; Böck JC; David I; Horowski R; Poewe W
Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264
[TBL] [Abstract][Full Text] [Related]
17. [Initial experiences with 123-Iodine-IBZM neuroreceptor scintigraphy in extrapyramidal disorders].
Pávics L; Dibó G; Ambrus E; Séra T; Vécsei L; Csernay L
Orv Hetil; 2000 May; 141(20):1073-7. PubMed ID: 10851890
[TBL] [Abstract][Full Text] [Related]
18. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
Hierholzer J; Castelli L; Cordes M; Schelosky L; Poewe W; Felix R
Radiol Med; 1996 Mar; 91(3):207-10. PubMed ID: 8628932
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
Schwarz J; Antonini A; Tatsch K; Kirsch CM; Oertel WH; Leenders KL
Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
